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Abstract: Current treatment protocol for postoperative
pain is to infuse anesthetic solution around nerves or into
the epidural space. This clinical practice is beset by the short
duration of the anesthetic effect unless the infusion is con-
tinuous. Continuous infusion, however, requires hospital-
ization of the patients, thereby increasing medical costs. In
addition, it also causes systemic accumulation of the drug.
We reported herein a novel treatment for the postoperative
pain by applying to the surgical site a biodegradable micro-
sphere-gel system for prolonged and localized release of
encapsulated anesthetic drugs. This lidocaine-containing
biodegradable poly(d,l-lactic acid) (PLA) microsphere sys-
tem, although being established previously by other inves-
tigators, was hindered by a burst release and a followed
rapid release of the drug within several hours in vitro. In this
article, we demonstrated that by a step-by-step modification
of the formulation, prolonged release of lidocaine, up to
several days in vitro, could be achieved. Differential scan-
ning calorimetry revealed a lower glass transition tempera-
ture for these lidocaine-loaded microspheres comparing to
that of lidocaine-free microspheres. This decreased Tg ex-
plained for the tendency of the lidocaine-loaded micro-
spheres to physically fuse at higher temperatures. In vitro
studies showed that microspheres, when loaded with 35%
lidocaine, yielded a threefold increase in the degradation
rate. The molecular weight of PLA of the drug-loaded mi-
crospheres was reduced by 50% within a period of 1 month.
Based on the results (of prolonged lidocaine release and
rapid PLA microsphere degradation), this lidocaine-loaded
PLA microsphere system could offer a simple solution to the
treatment of postoperative pain. © 2004 Wiley Periodicals,
Inc. J Biomed Mater Res 70A: 412–419, 2004
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INTRODUCTION
Techniques have already been developed to localize
anesthetic drugs in the nerve surroundings for the
treatment of postoperative pain. Severe chest pain
caused by heart surgery can be effectively relieved by
the technique of intercostal nerve block.1 In perform-
ing this technique, an anesthetic, such as lidocaine, is
injected locally into the intercostal space of the indi-
vidual. Although the beneficial effects of this tech-
nique have been well documented,2 this practice is
nevertheless limited by the short duration of the local
anesthetic effect that generally lasts for only a few
hours.
To achieve long-lasting effects, O’Kelly and Garry
introduced the technique of continuous intercostal
nerve block by repeated injection of anesthetics
through an indwelling catheter located in the intercos-
tal space.3 Despite improvement in relieving chest and
abdominal pain, this technique nevertheless remains
unpopular due to several possible complications; such
as accidental systemic absorption of the anesthetic
drug caused by misplacement or migration of the
catheter, as well as cumulative systemic absorption of
the drug after prolonged infusions.
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Epidural infusion of anesthetics has also been estab-
lished, and remains in major clinical practices.4–6 Even
with a high safety record, however, cardiovascular
effects like hypotension7,8 and tachyphylaxis9–12 were
still reported. Pharmacokinetics data, shown by
Sjogren and Wright,13 also indicated that the incidence
of tachyphylaxis and systemic toxicity resulting from
continuous lumbar epidural infusions of lidocaine
were significant.
To achieve a more effective and safe treatment for
pain, biodegradable microspheres have been applied
as a delivery system for prolonged release of the an-
esthetic drugs. The localized and sustained release of
anesthetics provided by such a system would reduce
the required drug dose for effective treatment, thereby
preventing the possibility of introducing accidental or
cumulative systemic drug absorption. Indeed, several
investigators14,15 have reported the preparation of li-
docaine-releasing PLA-based microspheres or nano-
particles. Such preparations, however, have all had a
common shortcoming of a large burst release followed
by a rapid release of lidocaine within several hours;
features that are not suitable for achieving the long-
term pain relief.
Herein, we report that by a stepwise modification of
the formulation of the PLA microspheres, sustained
release of lidocaine for several days was achieved in
vitro. Aside from the sustained release feature, these
microspheres, prepared from low molecular-weight
PLA, also possessed the proper degradation kinetics,
thereby avoiding the need for surgical removal. Based
on the prolonged lidocaine release and desirable deg-
radation rate, these microspheres could offer an attrac-
tive clinical approach in treating postoperative pain.
MATERIALS AND METHODS
Materials
Poloxamer 188 (PO188), lidocaine hydrochloride, lido-
caine (Lid), and sorbitan monooleate (Span80) were pur-
chased from Sigma (St. Louis, MO). Poly(d,l-lactic acid)
(PLA, iv 0.4, MW 20,000 Daltons) and Poly(vinyl alcohol)
(MW 6000 Daltons and 80 mol % hydrolyzed) were ob-
tained from Polyscience Inc. (Warrington, PA). Tetrahydro-
furan (THF, HPLC grade) was purchased from Fisher Sci-
entific (Pittsburgh, PA). Water was distilled and deionized
(ddH2O).
Preparation of lidocaine-loaded PLA microspheres
Microspheres were prepared using the oil/water solvent-
evaporation method.16 To investigate the effect of lidocaine
loading on the release kinetics, 250 mg PLA and various
amounts of lidocaine (75 to 375 mg) were dissolved in 2.5
mL methylene chloride. This prepared organic phase was
then mixed with 5 mL aqueous solution containing 10%
(w/v) PO188 and 7% NaCl, and the mixture was sonicated
for 2 min to produce an oil/water emulsion. The emulsion
was added to 25 mL aqueous solution containing 10% PO188
and 7% NaCl, stirred at 1700 rpm for 30 min, and followed
by evaporation of the solvent (methylene chloride) for 20
min on a rotary evaporator. The microspheres were col-
lected by centrifugation at 4°C and then freeze dried.
To examine the effect of the excipient (Span80) on lido-
caine release kinetics, various amounts of Span80 (0 to 37.5
mg), 250 mg PLA, and 375 mg lidocaine (Lid/PLA  150%)
were dissolved in 2.5 mL methylene chloride. Methylene
chloride was removed by rotary evaporation with slowly
heating the emulsion to 45°C. All the other experimental
conditions remained identical to those described earlier in
the preparation of microspheres.
To examine the effect of PLA concentration on lidocaine
release kinetics, two formulations of lidocaine-loaded micro-
spheres were prepared. One formulation was identical to
that described above in the study of the effect of Span80
(37.5 mg), whereas the other formulation consisted of twice
the amount of all involved constituents (while maintaining
the same Lid/PLA and Span80/PLA ratios). The stirring
time was extended to 2 h to naturally evaporate methylene
chloride without the use of an evaporator. The microspheres
were collected by centrifugation at 4°C and then washed
twice with 25 mL of ddH2O. All the other experimental
conditions remained identical to those described earlier in
the preparation of microspheres.
Lidocaine-free microspheres were prepared similarly to
those made above (500 mg PLA and 75 mg Span80) except in
the absence of lidocaine. All the microsphere preparations
were stored at 4°C under vacuum immediately following
their fabrication.
Characterization of microspheres
Surface morphology and particle size
The morphology and average particle size of the prepared
microspheres were examined by using a Philip FEG scan-
ning electron microscope (SEM). The average size was esti-
mated from the diameter of 100 randomly selected micro-
spheres.
Assay for lidocaine content
An Alltech (Deerfield, IL) reverse-phase high-pressure liq-
uid chromatography system (RP-HPLC) equipped with a
Prosphere C-18 RP-column was used to measure lidocaine
concentrations. Twenty milligrams of microspheres was dis-
solved in 5.5 mL of acetonitrile, followed by the addition of
9.5 mL of 0.05 M NaH2PO4 solution to precipitate the PLA
polymer. After filtration, 100 L of the filtrate was applied to
a reverse-phase HPLC equipped with a C18 column at a flow
rate of 1 mL/min. The column was eluted using 0.05 M
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NaH2PO4 solution containing 36.5% acetonitrile. The elution
peak was identified by using a UV detector at 215 nm.
The amount of injected lidocaine was estimated from a
preconstructed calibration curve. The loading content of
lidocaine in the microspheres was calculated as follows:
Lidocaine loading content (%)

weight of lidocaine in the microspheres
total weight of the microspheres  100%
The efficiency of lidocaine encapsulation was defined as
the weight percentage of the loaded lidocaine relative to the
initial dissolved lidocaine in the organic phase.
Glass transition temperature of microspheres
Measurements of the phase transition temperature of li-
docaine, PLA, and microspheres of the various lidocaine
loadings were carried out using a PerkinElmer (Wellesley,
MA) Model 7 Differential Scanning Calorimeter (DSC) at a
scanning rate of 10°C/min from 20 to 100°C. Melting points
(Tm) and glass transition temperatures (Tg) were determined
as the temperature at the onset of the peaks.
In vitro lidocaine release from the microspheres
A double-layer folded sieve box containing 50 mg of the
microspheres was immersed in a closed vial containing 5 mL
of 0.1 M phosphate buffer (pH 7.4). The vial was then placed
in a shaken water bath regulated at 30 rpm and 37°C. At
various times, the entire buffer was collected and replaced
with the same volume of a fresh buffer. Aliquots containing
100 L of the collected buffer were then applied to RP-HPLC
and assayed for the amount of released lidocaine. At the end
of the experiment, the microspheres were collected, freeze
dried, and assayed for the remaining lidocaine. Mass bal-
ance was conducted to verify that the amount of released
and remaining lidocaine matched that of the initial loading
dose.
Degradation studies of the PLA microspheres
PLA molecular weight changes
The molecular weights of PLA in both lidocaine-free and
-loaded microspheres after incubation were determined by
gel permeation chromatography using a Styragel column
(Waters, Milford, MA). In brief, 15 mg of the microspheres
was placed into a closed vial containing 5 mL of 0.1 M
phosphate buffer (pH 7.4) and incubated in a shaken water
bath at 37°C. At various times, the microspheres were col-
lected by centrifugation and washed twice with 5 mL of
ddH2O. The microspheres were freeze dried, dissolved in
THF, and then assayed for their molecular weights. The
peak, weight-averaged, and number-averaged molecular
weights (Mp, Mw, and Mn, respectively) of PLA were calcu-
lated using the PL Caliber Software (Polymer Laboratories,
Amherst, MA).
Surface morphology changes
Surface morphology of the PLA microspheres after incu-
bated at 37°C for various time periods was examined by




The lidocaine-free microspheres showed a smooth
surface [Fig. 1(a)], whereas lidocaine-loaded micro-
spheres exhibited a porous surface [Fig. 1(b)], with the
size of both types of microspheres being seen mostly
in the range of 1–50 m. Inside the microspheres,
however, both the lidocaine-free and -loaded micro-
spheres displayed porous structures, as observed by
SEM (data not shown). Formation of such porous
structures could be accounted for by the occurrence of
a phase separation in the PLA-dissolving organic
phase that was driven by a solvent (methylene chlo-
ride)–nonsolvent (water) exchange process; a phe-
nomenon discussed previously by Witte and cowork-
ers.17
Effects of the preparation method on the loading
content, encapsulation efficiency, and size of the
microspheres
Table I summarizes the results of the loading con-
tent and encapsulation efficiency of all the prepared
microspheres. As shown by the results in Experiments
1 to 3, the encapsulation efficiency increased with
increasing the initial lidocaine concentration in the
organic phase. Under a microscope, it was observed
that the higher the initial lidocaine concentration, the
more lidocaine crystals were formed in the water
phase. This observation implied that the water phase
was saturated by lidocaine that had leached out from
the microspheres. As a consequence, diffusion of lido-
caine out of the microspheres was retarded during the
fabrication process, resulting in higher encapsulation
efficiency for microspheres prepared with higher ini-
tial lidocaine concentrations (e.g., Experiment 3). Be-
cause the increase in temperature could significantly
increase the solubility and diffusion of lidocaine in
water, the encapsulation efficiency decreased when
the microsphere emulsions were heated to evaporate
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the methylene chloride solvent (e.g., compare Experi-
ment 3 with Experiment 4). The use of Span80, how-
ever, did not exert any obvious effects on either the
loading content or the encapsulation efficiency (see
Experiments 4 to 6). On the other hand, the extended
stirring employed in Experiment 7 had allowed more
lidocaine crystals to dissolve and subsequently diffuse
out of the microspheres, and consequently, resulted in
a reduction of encapsulation efficiency when the re-
sults were compared with those seen in Experiment 6.
In addition, results in Experiments 7 and 8 showed
that the loading content was increased by about three-
fold when the concentration of both PLA and lido-
caine was doubled. Nevertheless, altering the prepa-
ration method did not seem to change the average size
of the prepared microspheres (ranging from 7 to 9
m), except in Experiment 8 when a significant in-
crease in the microsphere size (i.e., to 14 m) was
observed with doubled PLA concentration. This in-
crease in size could be due to an increase in the vis-
cosity of the organic phase at the higher PLA concen-
tration.
Figure 1. The SEM photographs of: (a) lidocaine-free microspheres; and (b) lidocaine-loaded microspheres. Samples were
selected from Experiment 8 in Table I.
TABLE I
Effects of Preparation Methods on the Loading Content and Encapsulation Efficiency of the Microspheres
Release Expt. Set Expt. Number Loading Content (%)a Encapsulation Efficiency (%)b
Varying Lid/PLA 1c (Lid/PLA  30%) 3.8  0.5 13.1  1.6
2c (Lid/PLA  100%) 16.2  0.8 19.4  1.1
3c (Lid/PLA  150%) 28.5  1.7 27.3  0.8
Varying Span80/PLA 4d (Span80/PLA  0%) 17.9  0.6 14.5  0.6
5d (Span80/PLA  5%) 18.1  1.2 14.8  1.2





7e (PLA  10%, Lid  15%, Span80  1.5%) 10.5  1.0 7.8  0.8
8f (PLA  20%, Lid  30%, Span80  30%) 34.6  2.6 35.4  4.0
aLoading content (%)  (weight of lidocaine in the microspheres/total weight of the microspheres)  100%.
bEncapsulation efficiency was defined as the weight percentage of the loaded lidocaine relative to the initial dissolved
lidocaine in the organic phase.
cThe emulsion was stirred for 30 min followed by rotary evaporation of the solvent for 20 min.
dThe emulsion was stirred for 30 min followed by rotary evaporation of the solvent for 20 min with gradually heating up
to 45°C. The Lid/PLA ratio was maintained at 150%.
eThe emulsion was stirred for 2 h to naturally evaporate the solvent. The Lid/PLA ratio and Span 80/PLA ratio were
maintained respectively at 150 and 15%.
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Optimization of microsphere formulation
Effect of lid/PLA ratios
The effects of altering the Lid/PLA ratio (see Exper-
iments 1 to 3 in Table I) of the formulation on lidocaine
release are shown in Figure 2. The release rate was
significantly reduced when the Lid/PLA ratio was
increased from 100 to 150%; primarily due to the
crystallization of lidocaine within the microspheres.18
This finding was further confirmed in the later DSC
studies. In principle, in the presence of crystals, lido-
caine release was governed by two sequential steps:
(1) dissolution of the crystals, and (2) diffusion of the
dissolved lidocaine out of the microspheres. Owing to
this requirement of an additional crystal dissolution
step, lidocaine release was substantially retarded for
microspheres with a high loading content where lido-
caine crystals were formed.
Effect of Span80/PLA ratios
To further regulate the rate of lidocaine release,
Span80 was added during formulation of the micro-
spheres (see Experiments 4 to 6 in Table I). Figure 3
shows that a slower release rate was obtained when
the amount of Span80 was increased. This reduction in
release rate was believed to be due to the creation of a
hydrophobic environment by Span80, which subse-
quently hindered hydration of the microspheres. As is
known, water permeation into the microspheres is
essential for the lidocaine diffusion out of the micro-
spheres.
Effect of initial PLA concentrations
To examine the effect of PLA concentration on lido-
caine release, the initial concentration of PLA in the
organic phase was doubled. To maintain the same
Lid/PLA and Span 80/PLA ratios, the concentrations
of lidocaine and Span80 were also doubled accord-
ingly (see Experiments 7 and 8 in Table I). As shown in
Figure 4, the release rate of lidocaine decreased when
increasing the initial PLA concentration. In addition,
the degree of burst release of lidocaine (within the first
12 h) also decreased from 70 to 40% when the initial
concentration of PLA was raised from 10 to 20%. The
reduction in release rate was believed to be due to the
formation of a denser microsphere structure when a
higher PLA concentration was employed during mi-
crosphere formation.
Fusion of the microspheres
Under a microscope, it was observed that approxi-
mately 15% of the microspheres aggregated or, in-
Figure 3. Cumulative release of lidocaine (%) from micro-
spheres with a Span 80/PLA ratio of: () 0%; (Œ) 5%; and (F)
15%. Experiments conducted with the 0, 5, and 15% Span80/
PLA ratio corresponded to Experiments 4, 5, and 6 described
in Table I, respectively.
Figure 2. Cumulative release of lidocaine (%) from micro-
spheres with a Lid/PLA ratio of: (■) 30%; (F) 100%; and (Œ)
150%. Experiments conducted with 30, 100, and 150% Lid/
PLA ratio corresponded to Experiments 1, 2, and 3 described
in Table I, respectively.
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deed, fused to form particles of irregular shapes
during the freeze-drying process. The occurrence of
this fusion was far less significant if lidocaine was
not used or if poly(vinyl alcohol) rather than PO188
was used as an emulsifier during fabrication of the
microspheres. Therefore, it was speculated that fu-
sion of the microspheres was caused by either lido-
caine or PO188, or by both. Entrapment of a small
hydrophobic molecule like lidocaine may have ex-
erted a plasticizing effect on PLA, causing the mi-
crospheres to lose their mechanical resistance. The
presence of PO188 (PEG-PPG-PEG copolymer)
emulsifier in the interphase may also render the
microsphere surface to possess a brush-like struc-
ture (known to be formed by PEG), which, upon
freeze drying, could lead to entanglement of the
PEG chains19 between different particles, and con-
sequently, aggregation.
During storage of the microspheres, it was also
revealed that temperature increase would cause the
fusion. To further validate our theory, DSC studies
were conducted on microspheres with different li-
docaine loadings. Figure 5 shows that the glass tran-
sition temperature (Tg) of the microspheres de-
creased as the lidocaine loading increased,
supporting our theory that lidocaine was exerting a
plasticizing effect on the PLA-based microspheres.
This plasticizing effect would change the micro-
spheres from a glassy to a rubbery state, where the
transitional, rotational, and vibrational energies of
the polymer molecules were all enhanced. As a con-
sequence, the lidocaine-loaded microspheres would
yield a reduced Tg accompanied with a loss of their
mechanical resistance, rendering fusion of the mi-
crospheres to occur. To prevent this event, the mi-
crospheres need to be stored at 4°C under vacuum
immediately following their fabrication. It is also
interesting to note that, in agreement with findings
by other investigators,18 only one peak was ob-
served in the DSC diagrams of microspheres con-
taining no or little (11%) lidocaine [Fig. 5(c and d),
respectively], whereas two peaks were observed in
the microspheres containing high (35%) lidocaine
[Fig. 5(e)]. The former could be explained by the
formation of a homogeneous matrix with lidocaine
being evenly distributed within the microspheres,
whereas the latter was probably due to the occur-
rence of a heterogenous matrix consisting of the
PLA-dispersed lidocaine blends [the first peak in
Fig. 5(e)] and the lidocaine crystals [the following
peak in Fig. 5(e)].
Figure 5. The differential scanning calorimetry diagrams
of: (a) lidocaine, Tm  68°C; (b) PLA, Tg  50°C; (c) lido-
caine-free microspheres, Tg  48°C; (d) microspheres with a
lidocaine loading of 11%, Tg  41°C; and (e) microspheres
with a lidocaine loading of 35%, Tg  37°C (the first peak
from the left). Tm and Tg were defined as the temperature at
the onset of the peaks.
Figure 4. Cumulative release of lidocaine (%) from micro-
spheres with a PLA concentration (wt/v %) in the organic
phase of: (■) 10%; and (F) 20%. Experiments conducted with
the 10 and 20% PLA concentration corresponded to Exper-
iments 7 and 8 described in Table I, respectively.
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In vitro degradation of PLA microspheres
Change in molecular weight
Figure 6 shows that the lidocaine-loaded micro-
spheres (curves with solid lines) exhibited a faster
degradation rate than lidocaine-free microspheres; as
their molecular weight was reduced by 50% within 1
month of incubation compared to only 15% for the
lidocaine-free microspheres (curves with dotted lines).
Because ester bonds are susceptible to hydrolysis un-
der nonneutral pH conditions, degradation of the PLA
polymer can be catalyzed by the terminal carboxylic
groups produced by the hydrolysis of the ester bonds;
a process known as autocatalysis.20 In this regard, the
acidic or basic nature of the encapsulated drug can
also alter the degradation kinetics of PLA. The overall
degradation rate, therefore, depends on the pH bal-
ance between PLA and the encapsulated drugs inside
the microsphere. In the case of our lidocaine-loaded
microspheres, the number of lidocaine molecules was
many folds in excess over that of the carboxylic
groups, which existed only at the end of the polymer
chains. A basic microenvironment produced by the
basic lidocaine within the microspheres catalyzed the
cleavage of the ester bonds more rapidly than that by
the carboxylic groups alone in the lidocaine-free mi-
crospheres. As a consequence, the lidocaine-loaded
microspheres exhibited a more rapid degradation rate
than the lidocaine-free microspheres, as reflected by a
greater decrease in the molecular weights of PLA. For
comparison, molecular weights of the commercial
PLA were also determined, The Mp, Mw, and Mn of the
commercial PLA were estimated to be 13,138, 16,910,
and 14,159 Daltons, respectively. No significant
changes in molecular weights between the commercial
PLA and microspheres were observed, indicating that
no major PLA degradation occurred during prepara-
tion of the microspheres.
Change in morphology
Figure 7 presents the scanning electron micrographs
of the microspheres during the degradation process.
The lidocaine-free microspheres displayed an intact
surface after 2 weeks of incubation [Fig. 7(a)] and a
relatively smooth surface after 4 weeks of incubation
[Fig. 7(b)]; reflecting a slow degradation rate for these
microspheres. In contrast, the lidocaine-loaded micro-
spheres exhibited a smooth surface only after 3 days of
incubation [Fig. 7(c)], a rough surface after 2 weeks
[Fig. 7(d)], and a beehive shape after 4 weeks of incu-
bation [Fig. 7(e)]; implicitly reflecting a rapid degra-
dation. In addition, more than 95% of the lidocaine-
loaded microspheres were fused into irregular-shape
particles after 3 days, and only a small fraction of the
microspheres remained intact in their structures [see
Fig. 7(c)]. Nevertheless, the lidocaine-loaded micro-
spheres appear to be well suited for the proposed use
in postoperative pain treatment, because surgical re-
moval of the implanted microspheres could be
avoided due to their rapid degradation rate.
In summary, we demonstrated that by a stepwise
modification of the formulation of lidocaine-loaded
PLA-based microspheres, including optimization of
the lidocaine/PLA ratio and initial PLA concentration,
as well as incorporation of the Span80, a sustained
release of lidocaine over a period of several days could
be achieved. In vivo studies on sciatic nerve blocked
rats by utilizing the optimized microspheres devel-
oped in this study are currently in progress in our
laboratories.
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Figure 6. In vitro degradation kinetics of: (—, solid line)
lidocaine-loaded microspheres; and (---, dashed line) lido-
caine-free microspheres. Molecular weights were deter-
mined by gel permeation chromatography. Mw (F), Mp (*),
and Mn (E) represent the weight-averaged molecular
weight, molecular weight at the peak, and number-averaged
molecular weight, respectively. Microspheres were pre-
pared according to the conditions described in Experiment 8
in Table I.
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